Hubbert L, Embleton N, Wright A, Nicholson L. Is evidence on environmental impact included in health technology assessment and does it influence decision-making? (HTA56). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022

Heptinstall A, Teague R. Health technology assessment and reimbursement of medical devices in England, France, and Germany (HTA243). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022

Nicholson L, Adkins E, Karyanti M, Ong-Lim A, Shenoy B, Huoi C, et al. What is the true burden of diphtheria, tetanus, pertussis, and poliovirus in children aged 3-18 in Asia? A systematic literature review. Int J Infect Dis 2022;117:116-129.

Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis 2022;16:17534666221113647.

Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med 2022;9:7999912

Moschen A, Yossi S, Marjenberg Z, Heptinstall A, Pooley N, Marczewska A. The underestimated and overlooked burden of diarrhea and constipation in cancer patients. Curr Oncol Rep 2022;24(7):861-874

Skeldon G, Adkins E, Teague R. POSB291 A review of NICE Medtech Innovation Briefings (MIBS) of digital health technologies. Value Health 2021;24(S2).

Clarke AE, Pooley N, Marjenberg Z, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis. Semin Arthritis Rheum 2021;51(6):1230–41

Pego-Reigosa JM, Nicholson L, Pooley N, Langham S, Embleton N, Marjenberg Z, Barut V, Desta B, Wang X, Langham J, Hammond ER. A6:G6. Rheumatology (Oxford) 2021;60(1):60–72

Cook J, Bloom C, Lewis J, Marjenberg Z, Hernando Platz J, Langham S. Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. J Mark Access Health Policy 2021;9(1):1929757

Langham J, Barut V, Samnaliev M, Langham S, Weir S, Wang X, Desta B, Hammond E. Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 2021;5(3):rkab061

Kriz A, Wright A, Paulsson M, Tomlin S, Simchowitz V, Senterra T, Sheplev J. Cost-consequences analysis of increased utilization of triple-chamber-bag parenteral nutrition in preterm neonates in seven European countries. Nutrients 2020;12(9):2531

Kriz A, Wright A, Paulsson M, Tomlin S, Simchowitz V, Senterra T, Sheplev J. Cost-consequences analysis of increased utilization of triple-chamber-bag parenteral nutrition in preterm neonates in seven European countries. Nutrients 2020;12(9):2531

Wright A, Shepelev J, Kriz A. PAM5 Indirect calorimetry is a cost-saving strategy to manage patients in hospital intensive care. Value Health 2020;23(Suppl 2):S409

Vioix H, Wright A, de Silva S, Langham S, Gayle A, Soto J, Cook J, Capstick T, Quint J. PRS18 The clinical and cost impact of adherence to chronic obstructive pulmonary disease guideline recommendations in England- a cost consequence model. Value Health 2020;23(Suppl 2):S719

Langham J, Barut V, Samnaliev M, Langham S, Weir S, Wang X, Desta B, Hammond ER. SAT0216 Disease severity, comorbid conditions, treatment patterns, and flares in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort AnalysisIS. Ann Rheum Dis 2020;79(Suppl 1):1050–1

Samnaliev M, Barut V, Weir S, Langham J, Langham S, Wang X, Desta B, Hammond ER. THU0550 Health care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort study. Ann Rheum Dis 2020;79(Suppl 1):515–6

Skeldon G, Adkins E, Ayre S, Langham S, Nicholson L. PRO95 Patient engagement process in rare disease: how does it differ between countries? Value Health 2020;23(Suppl 2):S706

Marjenberg Z, Teague R, Skeldon G. PMU50 A review of exceptional circumstances marketing authorisations granted by the European Medicines Agency. Value Health 2020;23(Suppl 2):S611

Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond E. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020;6(2):e001247